Foxiga Korea Local Phase 4 Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.
Also called NCT02564926
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT02564926
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02564926. Randomized; no masking; primary purpose treatment. Start 2016-01-05 (actual); primary completion 2018-01-15 (actual). Results posted on 2019-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Foxiga Korea Local Phase 4 Study
- Acronym
- BEYOND
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02564926- Content hash
d69ecf2d17589f31a9e837e3ed0ce9c3fe5b68af71506be9f5d0f15bc40f728b